Hormone replacement therapy [topp]
tibolone [phsu, strd]
Raloxifene [orch, phsu]
Lipids [lipd]
Apolipoprotein A [aapp, bacs]
Apolipoprotein B [aapp, bacs]
Lipoprotein (a) [aapp, bacs]
Greek [popg]
postmenopausal [tmco]
Women [popg]
Study [mnob]
Estrogen [horm, phsu, strd]
regimens [inpr]
Continuous [idcn]
Combined [qlco]
Hormone replacement therapy [topp]
tibolone [phsu, strd]
Raloxifene [orch, phsu]
serum lipid [lbpr]
Apolipoprotein A [aapp, bacs]
Lipoprotein (a) [aapp, bacs]
Greek [popg]
postmenopausal [tmco]
Women [popg]
postmenopausal [tmco]
Women [popg]
Study [mnob]
prospective [resa]
Open [spco]
Design [acty]
Women [popg]
Assigned [ftcn]
Following [tmco]
regimens [inpr]
depend [medd]
risk factors [qnco]
Osteoporosis [dsyn]
Climacteric [orgf]
symptoms [ftcn]
Intact [qlco]
Uterus [bpoc]
Conjugated estrogen [horm, phsu, strd]
Equine [mamm]
mg% [qnco]
cee [orch]
N NOS [aapp, imft]
Continuous [idcn]
Combined [qlco]
cee [orch]
mg/mg [qnco]
Plus [qlco]
medroxyprogesterone acetate [horm, phsu, strd]
N NOS [aapp, imft]
Continuous [idcn]
Combined [qlco]
17beta estradiol [horm, phsu, strd]
mg/mg [qnco]
Plus [qlco]
Norethisterone acetate [horm, phsu, strd]
N NOS [aapp, imft]
tibolone 2.5 MG [clnd]
N NOS [aapp, imft]
Raloxifene 60 MG [clnd]
N NOS [aapp, imft]
Five [qnco]
postmenopausal [tmco]
Women [popg]
Indications [idcn]
Hormone replacement therapy [topp]
Total Cholesterol [lbpr]
Low density lipoprotein [aapp, bacs, lipd]
High Density Lipoprotein Cholesterol [bacs, lipd]
Triglyceride [bacs, lipd]
Apolipoprotein A [aapp, bacs]
Apolipoprotein B [aapp, bacs]
Lipoprotein (a) [aapp, bacs]
Lp(a) [aapp, bacs]
Assessed [acty]
Subject [grup]
baseline [bodm]
months [tmco]
therapy [ftcn]
therapy [ftcn]
regimens [inpr]
lowered [spco]
Total Cholesterol [lbpr]
Compared [acty]
baseline [bodm]
Decrease [qlco]
Prominent [qlco]
Women [popg]
high cholesterol level [fndg]
baseline [bodm]
Decrease [qlco]
Cholesterol, LDL [bacs, strd]
Decreased [qnco]
cee [orch]
cee [orch]
mg% [qnco]
Plus [qlco]
medroxyprogesterone acetate [horm, phsu, strd]
Raloxifene [orch, phsu]
Group [idcn]
Women [popg]
Exhibit [inpr]
Decrease [qlco]
Cholesterol, LDL [bacs, strd]
therapy [ftcn]
Group [idcn]
Triglyceride level [lbtr]
Increased [qnco]
cee [orch]
cee [orch]
mg% [qnco]
Plus [qlco]
medroxyprogesterone acetate [horm, phsu, strd]
Group [idcn]
Norethisterone acetate [horm, phsu, strd]
Triglyceride level [lbtr]
tibolone [phsu, strd]
Decreased [qnco]
Triglyceride level [lbtr]
Markedly [qlco]
Raloxifene [orch, phsu]
Triglyceride [bacs, lipd]
lowering [spco]
High Density Lipoprotein Cholesterol [bacs, lipd]
Apo-A [aapp, bacs]
Increased [qnco]
cee [orch]
cee [orch]
mg% [qnco]
Plus [qlco]
medroxyprogesterone acetate [horm, phsu, strd]
High Density Lipoprotein Cholesterol [bacs, lipd]
Apolipoprotein A [aapp, bacs]
Decreased [qnco]
tibolone [phsu, strd]
High Density Lipoprotein Cholesterol [bacs, lipd]
Apolipoprotein A [aapp, bacs]
therapy [ftcn]
regimens [inpr]
Raloxifene [orch, phsu]
lowered [spco]
Lp(a) [aapp, bacs]
tibolone [phsu, strd]
therapy [ftcn]
Regimen [topp]
Lipid level [lbtr]
Lipoprotein [aapp, bacs]
exerting [orgf]
Favorable [qlco]
Unfavorable [qlco]
Modification [ftcn]
Women [popg]
Benefit [qnco]
Cholesterol [bacs, strd]
lowering [spco]
Estrogen Replacement Therapy [topp]
Hormone replacement therapy [topp]
choice [inbe]
Regimen [topp]
Based [ftcn]
Needs [qlco]
Indications [idcn]
lipid lipoprotein [aapp, lipd]
Profile [lbpr]
